<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Iloperidone</strong></td></tr><tr><th>Accession Number</th><td><strong>DB04946</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. made initial inquiries into the drug; however, in May 1996, they discontinued research, and in June 1997 gave research rights to Titan Pharmaceuticals. Titan then handed over worldwide development, manufacturing and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals announced that the Phase <span class="caps">III</span> development rights have been acquired by Vanda Pharmaceuticals. <span class="caps">FDA</span> approved on May 9, 2009.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB04946/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB04946/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB04946.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB04946.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB04946.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB04946.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB04946.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB04946">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>HP 873</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Fanapt </td><td>Vanda Pharmaceuticals Inc. </td></tr><tr><td>Fiapta</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Zomaril</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>133454-47-4</td></tr><tr><th>Weight</th><td>Average: 426.4806<br>Monoisotopic: 426.195485567</td></tr><tr><th>Chemical Formula</th><td>C<sub>24</sub>H<sub>27</sub>FN<sub>2</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>XMXHEBAFVSFQEX-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C24H27FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-15,17H,3,8-13H2,1-2H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-(4-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy}-3-methoxyphenyl)ethan-1-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=C(OCCCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C=CC(=C1)C(C)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzisoxazoles</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Benzisoxazoles</td></tr><tr><th>Alternative parents</th><td>Acetophenones; Anisoles; Benzoyl Derivatives; Fluorobenzenes; Alkyl Aryl Ethers; Piperidines; Aryl Fluorides; Isoxazoles; Ketones; Tertiary Amines; Polyamines; Enolates; Organofluorides</td></tr><tr><th>Substituents</th><td>benzoyl; phenol ether; anisole; alkyl aryl ether; fluorobenzene; benzene; aryl fluoride; aryl halide; piperidine; azole; isoxazole; tertiary amine; ketone; enolate; ether; polyamine; organohalogen; carbonyl group; organofluoride; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzisoxazoles. These are aromatic compounds containing a benzene ring fused to an isoxazole ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Treatment of acute schizophrenia. </td></tr><tr><th>Pharmacodynamics</th><td>Iloperidone shows high affinity and maximal receptor occupancy for dopamine D2 receptors in the caudate nucleus and putamen of the brains of schizophrenic patients. The improvement in cognition is attributed to iloperidone's high affinity for  &#945; adrenergic receptors. Iloperidone also binds with high affinity to serotonin 5-HT2a and dopamine 3 receptors. Iloperidone binds with moderate affinity to dopamine D4, serotonin 5-HT6 and 5-HT7, and norepinephrine NE&#945;1 receptors. Furthermore, iloperidone binds with weak affinity to serotonin 5-HT1A, dopamine D1, and histamine H1 receptors. </td></tr><tr><th>Mechanism of action</th><td>Iloperidone is a dopamine D2 and 5-HT2A receptor antagonist and acts as a neuroleptic agent. 

</td></tr><tr><th>Absorption</th><td>Well absorbed from the GI tract and Cmax is reached within 2-4 hours.
Steady-state concentration is achieved in 3-4 days post-administration of iloperidone. Relative bioavailability of the tablet formulation compared to oral solution is 96%. Accumulation occurs in a predictable fashion. </td></tr><tr><th>Volume of distribution</th><td><p>Apparent Vd = 1340-2800 L</p></td></tr><tr><th>Protein binding</th><td>95% of iloperidone is bound to protein. Percent bound is not altered by renal or hepatic impairment or combination therapy with ketoconazole. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Iloperidone is hepatically metabolized by cytochrome enzymes which mediates O-dealkylation (CYP3A4), hydroxylation (CYP2D6), and decarboxylation/reduction processes. Metabolites formed are P89, P95, and P88. The minor metabolite is P89, whereas P95 and P88 are the major ones. The affinity of the iloperidone metabolite P88 is generally equal or less than that of the parent compound. In contrast, the metabolite P95 only shows affinity for 5-HT2A (Ki value of 3.91) and the NE&#945;1A, NE&#945;1B, NE&#945;1D, and NE&#945;2C receptors (Ki values of 4.7, 2.7, 8.8 and 4.7 nM respectively).</p></td></tr><tr><th>Route of elimination</th><td>Renal (in which </td></tr><tr><th>Half life</th><td>The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM) are 18, 26 and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37 and 31 hours, respectively. </td></tr><tr><th>Clearance</th><td><p>Apparent clearance (clearance/bioavilability) = 47-102 L/h.</p></td></tr><tr><th>Toxicity</th><td>Commonly observed adverse reactions (incidence &#8805;5% and two-fold greater than placebo) were: dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight increased.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9848</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5513</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6668</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8242</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.9268</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.5726</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.9051</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.892</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7409</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6111</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5061</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.886</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.6257</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.6777</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.9008</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6314
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8699
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7862 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.6563
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.7945
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Vanda pharmaceuticals inc</li></ul></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Clarithromycin is a strong CYP3A4 inhibitor that increases serum concentration of iloperidone. Reduce dose of iloperidone by 50% </td></tr><tr><td><a href="/drugs/DB00907">Cocaine</a></td><td>CYP2D6 Inhibitors (Strong) such as cocaine may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone. Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor. </td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone. Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor. </td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Fluoxetine is a strong CYP2D6 inhibitor that increases serum concentration of iloperidone. Reduce dose of iloperidone by 50% </td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole is a strong CYP3A4 inhibitor that increases serum concentration of iloperidone and likelihood of observing adverse effects such as QT prolongation. Reduce dose of iloperidone by 50% </td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00715">Paroxetine</a></td><td>Paroxetine is a strong CYP2D6 inhibitor that increases serum concentration of iloperidone and likelihood of observing adverse effects such as QT prolongation. Reduce dose of iloperidone by 50% </td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li> Administration of iloperidone with a standard high-fat meal did not significantly affect the Cmax or AUC of iloperidone, P88, or P95, but delayed Tmax by 1 hour for iloperidone, 2 hours for P88 and 6 hours for P95. </li>
<li>Can be taken with or without meals</li></ul></td></tr></tbody></table>